326 results on '"Gupta, Shiv K."'
Search Results
52. Robustness and Optimality as Criteria for Strategic Decisions
53. Reply to Professor D. J. White
54. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma
55. In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
56. Hematopoietic cells from Gadd45a- and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis
57. A Small Correction to a Paper of Vandermonde
58. Conserved nucleotide sequences in highly expressed genes in plants
59. EXTH-01. INHIBITION OF DNA-PKcs BY M3814 POTENTIATES EFFICACY OF IONIZING RADIATION IN PATIENT-DERIVED XENOGRAFTS OF MELANOMA BRAIN METASTASES
60. TMOD-15. EFFICACY OF THE MDM2 INHIBITOR KRT-232 IN GLIOBLASTOMA PATIENT-DERIVED XENOGRAFT MODELS
61. Abstract 6276: Brain penetrant MDM2 inhibitor RG7388 extends survival benefit of radiation treatment in select glioblastoma patient-derived xenograft models
62. Abstract 6506: Targeting ATM with AZD1390 for radio-sensitization of glioblastoma patient derived xenografts
63. Abstract 1381: Inhibition of DNA-PKcs by M3814 potentiates efficacy of ionizing radiation in patient derived xenografts of melanoma brain metastases
64. Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of cdkn2b
65. The Karush–Kuhn–Tucker conditions for multiple objective fractional interval valued optimization problems
66. Integrin α9β1: Unique signaling pathways reveal diverse biological roles
67. In vitro proliferation of shoots and regeneration of cotton
68. Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal
69. Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma
70. The concept of corporate social responsibility applied to trade associations
71. Molecular profiling of long-term IDH-wildtype glioblastoma survivors
72. Abstract 3870: The addition of CB-839 to temozolomide significantly reduces glioma aspartate and glutamate in an IDH mutated patient derived glioma xenograft model
73. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas
74. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
75. Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor
76. A novel design for porphyrin based D–s–A systems as molecular rectifiers† †Electronic supplementary information (ESI) available: Schematic representation of the electro-grafting mechanism, the electrochemical deposition of undecene, I–V characteristics of the blank Si sample and C-11 alkyl monolayers on a silicon wafer, XPS of the monolayers and the optimised geometry of the 5b congener with reverse geometry. Tables of atom coordinates and absolute energies used for theoretical calculations. See DOI: 10.1039/c5sc03590b
77. Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of poly (ADP-ribose) polymerase inhibition on temozolomide therapy in glioblastoma
78. Invex and quasi-invex NCP functions and their properties.
79. The Karush–Kuhn–Tucker conditions for multiple objective fractional interval valued optimization problems.
80. Abstract 4112: Synthetic luciferin, CycLuc1, improves bioluminescence imaging for intracranial glioblastoma xenografts
81. Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
82. Evaluating Slot Machine Placement on the Casino Floor
83. Mathematical Models in Marketing
84. Differential Equation Approach to Marketing
85. International Environmental Problems: Systems Approach Used to Identify Scientific and Political Perceptions and Responses
86. Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma
87. Abstract 1109: MutSα and MutSβ mismatch repair complexes differentially regulate temozolomide efficacy & sensitizing effects of veliparib in glioblastoma cells
88. Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex
89. Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells
90. DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme
91. DNA repair capacity in multiple pathways predicts chemoresistance in glioblastoma multiforme
92. Abstract 340: Talazoparib enhances low-dose temozolomide efficacy in flank glioblastoma models, but intracranial efficacy is constrained by limited brain distribution
93. A novel design for porphyrin based D–s–A systems as molecular rectifiers
94. Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts1
95. Targeting Bromodomain and External Domain Epigenetic Reader Protein As Effective Strategy for Double-Hit and Triple-Hit B-Cell Lymphoma
96. Reply to Comments by Dr. R. G. Dyson
97. Fast Response and High Sensitivity of ZnO Nanowires—Cobalt Phthalocyanine Heterojunction Based H2S Sensor
98. Abstract 3505: Inhibition of PARP activity by BGB-290 potentiates efficacy of temozolomide in patient derived xenografts of glioblastoma multiforme
99. Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
100. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.